Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human trial of ADI-100 in psoriasis

Next Previous
Trial Profile

A first-in-human trial of ADI-100 in psoriasis

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADI 100 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors ADiTxT Therapeutics

Most Recent Events

  • 18 Aug 2023 According to a ADiTxT Therapeutics media release, Clinical trial applications for psoriasis is expected to be filed with the German Health Authority in Q1 2024. Stability program is completed and the company intend to finalize the CTA documents and apply for regulatory approval to perform clinical trials in T1D and psoriasis.
  • 18 Aug 2023 According to a ADiTxT Therapeutics media release, Clinical grade manufacturing of clinical grade drug substances (DNA plasmids) has been completed and GMP formulation of clinical grade ADI-100™, to be used for the first-in-human studies in subjects with psoriatic lesions, is expected to be initiated.
  • 31 Oct 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top